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Abstract 
Context: Patients with classic congenital adrenal hyperplasia (CAH) often do not achieve 
their full growth potential. Adrenarche may accelerate bone maturation and thereby 
result in decreased growth in CAH.
Objective: The study aimed to analyze the impact of growth during adrenarche on final 
height of adequately treated classic CAH patients.
Methods: This retrospective, multicenter study (4 academic pediatric endocrinology 
centers) included 41 patients with classical CAH, born 1990-2012. We assessed skeletal 
maturation (bone age), growth velocity, and (projected) adult height outcomes, and 
analyzed potential influencing factors, such as sex, genotype, and glucocorticoid therapy.
Results: Patients with classic CAH were shorter than peers (−0.4 SDS ± 0.8 SD) and their 
parents (corrected final height −0.6 SDS ± 1.0 SD). Analysis of growth during adrenarche 
revealed 2 different growth patterns: patients with accelerating bone age (49%), and 
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with accelerating BA-CA were taller than the normal population during adrenarche years 
(P = 0.001) and were predicted to achieve lower adult height SDS (−0.9 SDS [95% CI, 
−1.3; −0.5]) than nonaccelerating patients when assessed during adrenarche (0.2 SDS 
[95% CI, −0.3; 0.8]). Final adult height was similarly reduced in both accelerating and 
nonaccelerating BA-CA groups (−0.4 SDS [95% CI, −0.9; 0.1] vs −0.3 SDS [95% CI, [−0.8; 
0.1]).
Conclusion: Patients with and without significant bone age advancement, and thus 
differing height prediction during adrenarche, showed similar (predicted) final height 
when reassessed during pubertal years. Bone age alone should not be used during 
adrenarche as clinical marker for metabolic control in CAH treatment.
Key Words: growth, adrenarche, classic CAH, final height prediction
Congenital adrenal hyperplasia (CAH) comprises a group 
of autosomal recessive disorders, in which an enzymatic 
deficiency leads to impaired glucocorticoid biosynthesis. 
The most common form of CAH is 21-hydroxylase defi-
ciency due to variants in the CYP21A2 gene, with a fre-
quency of about 1 in 10 000 to 15 000 births (1). Because 
the glucocorticoid feedback system remains intact with 
CAH, the hypothalamus and anterior pituitary gland re-
spond to low cortisol levels by releasing corticotropin 
(CRH) and adrenocorticotropin (ACTH) hormones, 
which increase steroid precursor synthesis upstream of 
the enzymatic defect. In 21-hydroxylase deficiency, ac-
cumulating precursors are converted to androgens that 
cause the typical clinical features of CAH. These include 
virilization of girls at birth, and adrenal insufficiency 
soon after birth in both sexes. Precocious pseudopuberty, 
growth acceleration, and advancement of bone age may 
occur in insufficiently treated infants, which may lead to 
reduced final height. Adverse outcomes are testicular ad-
renal rest tumors in boys, hirsutism, and menstrual cycle 
disturbances in girls, as well as fertility problems in both 
sexes (1).
Management of children with CAH remains a challenge. 
Because patients with a severe loss of 21-hydroxylase ac-
tivity require lifelong replacement therapy with gluco-
corticoids and mineralocorticoids, finding the balance 
between hyperandrogenism and hypercortisolism 
is important. Undertreatment leads to insufficient 
hypothalamic-pituitary-adrenal axis suppression and ex-
cessive androgen production, which accelerates growth (2), 
while overtreatment with glucocorticoids directly inhibits 
growth (3). Throughout childhood and adolescence, close 
monitoring of biochemical markers and adjusting gluco-
corticoid dosage are necessary (4, 5).
Patients with CAH often do not reach their full growth 
potential (2, 6-8). Important factors that contribute to re-
duced final height are overtreatment with glucocorticoids, 
poor patient compliance, or direct effects of glucocorticoids 
on growth and sex hormone secretion, or on bone, col-
lagen, and muscle formation (3, 9, 10).
However, the exact contribution of these and unknown 
other factors remains unclear, but growth-inhibiting fac-
tors may have a different impact during different devel-
opmental periods in childhood (2). Puberty is a critical 
phase when changes in glucocorticoid pharmacokinetics 
complicate metabolic control and compromise height 
gain (11-13). An additional, earlier phase when growth 
may be influenced adversely is adrenarche, the onset of 
androgen production in the developing/maturing adrenal 
zona reticularis (zR) (14). During adrenarche, some CAH 
children with previously adequate metabolic control and 
skeletal maturation present with increased growth velocity 
and advancing bone age, and thus are assumed to require 
higher glucocorticoid doses.
Growth during adrenarche has been studied in healthy 
children extensively (14-19), but data on this topic in chil-
dren with CAH are scarce. It remains unclear if comprom-
ised final height in CAH individuals originates in part from 
altered growth characteristics during adrenarche.
We therefore aimed to describe trends of skeletal mat-
uration (bone age), height, growth velocity, and projected 
adult height in children with classical CAH throughout 
adrenarche and puberty. We also investigated potential risk 
factors for lower final height outcomes.
Methods
Study Population and Procedure
This is a retrospective multicenter study using patient data 
from digital and paper charts of 4 Swiss pediatric endo-
crinology centers. We received ethics approval through 
the Swiss DSD Cohort Study Registry, from the Ethics 
Committees of the Cantons of Bern, Zurich, Vaud, Geneva, 
and the Ethics Committees of Northwestern and Central 
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We included children born from 1990 to 2012 with a 
neonatal diagnosis of classic CAH due to 21-hydroxylase 
deficiency and continuous follow-up care in the respective 
clinic between diagnosis and 9  years of age (Fig. 1). We 
excluded patients who received growth-promoting treat-
ments (growth hormone [n = 1]), puberty blockage (n = 1), 
aromatase inhibitors (n = 2), or who did not provide in-
formed consent. In Switzerland, nationwide screening for 
CAH was introduced in 1992. Five study patients were 
born between 1990 and 1992 but were still diagnosed in 
the first month of life.
We extracted clinical parameters from medical charts, 
including results from gene analyses, hand x-ray images, 
auxological measurements (weight and height), par-
ental height, pubertal status (Tanner stage), medication, 
and laboratory measurements (17-hydroxyprogesterone 
[17-OHP], dehydroepiandrosterone sulfate [DHEAS], 
androstenedione).
We classified results from gene analyses according to 
international guidelines (1) into 4 groups (0, A, B, C) as 
described by Speiser et al (20).
Bone age was determined in yearly intervals using radio-
graphs of the hand and the method of Greulich and Pyle 
(21). We reassessed all bone ages to avoid systematic meas-
urement error between the 4 centers. We defined bone age 
retardation as the difference between bone age and chrono-
logical age (BA-CA). Standard deviation scores (SDS) for 
height, weight, body mass index (BMI) and growth velocity 
were derived using the LMS method (22) for Swiss refer-
ences (23). Corrected final height SDS were calculated as 
the difference between final height SDS and target height 
SDS. We calculated estimated adult height based on bone 
age and height according to the Bayley-Pinneau method 
(24), as well as with the adapted values proposed for 
CAH patients by Bonfig and Schwarz (25). Parental target 
height was calculated as the mean height of both parents 
± 6.5 cm for boys and girls, respectively. BMI was calcu-
lated as weight in kilograms divided by square height in 
meters. We considered patients with a growth velocity less 
than 1 cm/year and/or older than 18 years to have reached 
final height.
We used the Tanner method to define pubertal stages 
(26). We considered children with Tanner stage 1 as pre-
pubertal, girls with thelarche B2 and G2 in boys as pu-
bertal, and pubarche as P2 in both sexes. We grouped 
longitudinal data in 3 defined time periods: (a) Before 
adrenarche: aged <6 years; (b) Adrenarche: aged ≥6 years 
to puberty onset (corresponding to B2 in girls and G2 in 
boys); and (c) Puberty: after puberty onset.
We determined equivalent of hydrocortisone dos-
ages in mg/m2/d for all visits to standardize assessment 
of glucocorticoid treatment. The glucocorticoid effect of 
prednisolone is estimated to be 4 times as potent as hydro-
cortisone (5). Patients did not show signs of significant 
chronic over- or undertreatment during the observation 
period. We assigned patients as having received hydrocor-
tisone dosages of <15 mg/m2/day or ≥15 mg/m2/day, and 
fludrocortisone dosages of <50 µg/day or ≥50 µg/day. We 
categorized patients into those with androstenedione levels 
<11 nmol/L or ≥11 nmol/L, and those with 17-OHP levels 
<30 nmol/L or ≥30 nmol/L.
Statistical Analyses
We compared age at entering a certain sexual development 
period (onset of Tanner stages) between patients with CAH 
and healthy European references using the Student t test (27).
We compared bone age and growth between girls and 
boys; between children aged <6 years and children during 
adrenarche; and between children during adrenarche and 
children during puberty using Wilcoxon rank-sum tests.
We categorized the cohort into 2 groups depending on 
their bone age progression: We categorized children whose 
yearly mean BA-CA was at least 0.1 year higher at age 6 
to 9  years than <6 years as accelerating patients, and all 
other as nonaccelerating patients. We chose a cutoff at age 
9  years to exclude pubertal growth spurt. We calculated 
means and 95% CIs by time period, and by bone age pro-
gression group. If 95% CIs did not include the mean of the 
respective other group, we assumed differences between ac-
celerating and nonaccelerating patients.
We performed linear mixed effects models to identify 
factors associated with estimated final height SDS (Bayley 
and Pinneau (24)) separately for adrenarche and puberty. 
Estimated final height SDS data were normally distrib-
uted. We included patients and age as random effects and 
bone age progression, sex, Speiser classification (20), gluco-
corticoid dose, fludrocortisone dose, androstenedione, and 
17-OHP as fixed effects. Because of the relatively small 
sample size, we ran univariable models only.
We used the statistical software Stata (Version 16, 
Stata Corporation, Austin, Texas) for data preparation, 
descriptive statistics, and calculation and visualizing of 
linear mixed model parameters. We created line charts and 
boxplots using the ggplot2 package for RStudio version 
Tiger Daylily.
Results
We included data from 41 patients with classic CAH in 
our study (Table 1). Of those, 15 were boys (37%) and 
26 girls (63%). Most patients (31/41, 76%) had CYP21A2 
genotyping to confirm diagnosis. Among those children 
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0, 12/31 (39%) in category A, 13/31 (42%) in category B, 
and 2/31 (6%) in category C. The most frequent mutations 
were deletions (16/31, 52%), intron 2-splice mutations 
(14/31, 45%), and I172N (13/31, 42%). At the time of the 
study, 37/41 CAH patients had developed pubarche, at a 
mean age of 10.5 years in girls and 11.7 years in boys. At 
the time of study, puberty had started in 35/41 of CAH pa-
tients. In girls, pubarche started at a mean age of 10.5 years 
and puberty at 10.3 years, slightly earlier than in European 
references (P2: 11.3 years; B2: 10.9 years) (27). Timing of 
pubarche or adrenarche was similar between boys with 
CAH (P2: 11.7 years; B2: 12.1 years) and European refer-
ences (P2: 11.9; G2: 11.8) (27).
Mean BMI was within normal range in both girls and 
boys (mean 0.3–1.3 SDS), but it increased from before 
adrenarche to adrenarche in both sexes (P < 0.05) (Fig. 
2A). Patients received a mean hydrocortisone dose of 14.1 
to 16.2  mg/m2/d, which did not vary between develop-
mental periods (P = 0.349). Almost all (40/41) patients re-
ceived fludrocortisone.
Figure 1. Recruitment scheme. Figure 1 depicts the patients recruited according to the inclusion criteria age, informed consent, and diagnosis with 
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Growth Characteristics of Boys and Girls With 
CAH During Adrenarche and Puberty
To assess the growth characteristics of CAH patients, 
we analyzed longitudinal growth data in 3 time period 
groups: before adrenarche, adrenarche, and puberty 
(Table 2 and Fig. 2). Of the 41 children with CAH, 20/26 
girls and 7/15 boys achieved final height with a mean 
of 160.1 and 176.4 cm respectively. Mean height SDS at 
age <6 years was in the low normal range and increased 
from <6 years to adrenarche (P = 0.011) (Fig. 2B). Mean 
growth velocity was higher in boys than in girls before 
adrenarche, but not afterward (Table 2). We observed 
that mean growth velocity in boys was higher before 
adrenarche than at puberty, while no difference between 
age periods was observed in girls (Fig. 2C). In both sexes, 
mean BA-CA was slightly delayed before adrenarche 
and increased with adrenarche (−0.5  years ± 0.7 SD vs 
0.1 years ± 1.4 SD; P = 0.014, Fig. 2D, Table 2). We also 
observed a difference in mean BA-CA between girls and 
boys from before adrenarche to puberty (Fig. 2D).
When we compared estimated final height SDS between 
boys and girls, we found that boys had a higher estimated 
final height SDS according to Bayley and Pinneau (24) 
than girls during adrenarche (boys: 0.3 SDS ± 1.0 SD vs 
girls: −0.7 SDS ± 1.1 SD) and during puberty (boys: 0.3 
SDS ± 1.1 SD vs girls: −0.7 SDS ± 0.9 SD) (Table 2). There 
was no difference between the time periods in either girls or 
boys for Bayley and Pinneau estimations (Fig. 2E). By con-
trast, estimated final height SDS increased from adrenarche 
to puberty in girls and boys when calculating with the 
Bonfig and Schwarz method (Fig. 2F).
Do CAH Children Who Advance Their Bone Age 
During Adrenarche Achieve a Lower Final Height?
When we divided CAH children by bone age progression 
during adrenarche, half of the children (20/41, 49%) had 
accelerating bone age, and in the other half (21/41, 51%) 
bone age progressed normally (Fig. 3A, B). Mean height 
SDS during adrenarche was higher in children with accel-
erating BA-CA than in those with nonaccelerating BA-CA 
(0.5 SDS [95% CI, 0.2; 0.9]) vs −0.3 SDS [95% CI, −0.9; 
0.2]) (Fig. 3C, D). During puberty, these differences dis-
appeared (Fig. 3B and 3D). Growth velocity was higher 
before adrenarche in children with bone age progression 
during adrenarche and decreased thereafter (Fig. 3E).
Children with accelerating BA-CA during adrenarche 
had a lower estimated final height according to Bayley and 
Pinneau than those whose bone age was not progressing 
(−0.9 SDS [95% CI, −1.3; −0.5] vs 0.2 SDS [95% CI, −0.3; 
0.8]), but this difference disappeared by the time they 
reached puberty (Fig. 3G); the same was true when using 
the Bonfig and Schwarz method (Fig. 3H).
Factors Associated With Estimated Final Height
During adrenarche, accelerating bone age (r −1.12 [95% 
CI, −1.7; −0.5]), female sex (r −0.98 [95% CI, −1.6; −0.3]), 
and 17-OHP >30  nmol/L (r −0.37 [95% CI, −0.7; 0.0]) 
were associated with lower estimated final height, and 
fludrocortisone doses >50  µg/day (r 0.34 [95% CI, 0.0; 
0.6]) were associated with higher estimated final height 
(Fig. 4A). During puberty, female sex (r −1.00 [95% CI, 
−1.7; −0.3]) was associated with lower, and androstene-
dione >11 nmol/L (r 0.25 [95% CI, 0.1; 0.4]) with higher 
estimated final height (Fig. 4B). Children with a genetic 
diagnosis of Speiser category C (r 1.67 [ 95% CI, 0.9; 2.4]) 
seemed to be more likely to achieve a higher final height 
than children of other CAH diagnoses, but differences were 
not statistically significant, probably because some genetic 
subgroups contained only a few patients.
Discussion
Our study found that final height in patients with classic 
CAH is still compromised, although less than in earlier 
days. We therefore investigated whether height loss may be 
due to events occurring during the years of adrenarche. We 
identified 2 growth patterns during adrenarche, patients 
whose bone age accelerated in relation to their chrono-
logical age, and patients whose bone age progressed nor-
mally. Patients with accelerating BA-CA were taller during 
adrenarche and had lower estimated adult height than 
those with nonaccelerating BA-CA during adrenarche. 
During puberty, however, estimated final height was similar 
in both groups. Final height in both groups was similarly 
lower compared to the normal population and in relation 
to parental target height. Thus, we found that the transient 
acceleration of bone age during adrenarche cannot explain 
the reduced final height in CAH patients.
Similar to our results, a meta-analysis of 35 studies found 
that patients with classic CAH under corticosteroid treatment 
were shorter than healthy controls, and shorter than their 
parents (7). However, mean final height of our CAH patients 
was higher than in most previous studies (7), possibly because 
most patients reported in previous studies received higher 
average glucocorticoid doses of 15 to 20 mg/m2/d. Our pa-
tients received 14.7 or 15.4 mg/m2/d during adrenarche and 
puberty, respectively, as recommended by Bonfig et al (4, 28). 
In addition, neonatal screening allowed for rapid diagnosis and 
treatment in our patients, contrary to some patients included 
in previous studies. Similar to our study, the meta-analysis also 
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outcomes (7). This positive effect might reflect early diagnosis 
and treatment in salt-wasting CAH children compared with 
later manifesting and treated non-salt-wasting CAH. All but 
1 patient in our study received mineralocorticoids. Differences 
in patient compliance or in health care systems may in add-
ition explain some differences in growth outcomes between 
our and previous studies.
In our CAH patients, pubertal growth spurt was similar 
to healthy children (29). This is in contrast to the study by 
Bonfig et al (28), where pubertal growth was lower in CAH 
than in healthy children. This suggests that pubertal growth 
did not compromise final height in our patients.
Female gender was a risk factor for low final height 
prediction in adrenarche and puberty. But studies on 
Figure 2. Growth characteristics of boys and girls with classic CAH before, during and after adrenarche. Shown are growth data of boys and girls, 
depicted in box plots and divided into 3 age groups: before adrenarche, adrenarche, and puberty. From top left to bottom right, parameters depicted 
as box plots are A, mean BMI SDS; B, mean height SDS; C, mean growth velocity SDS; D, mean bone age—chronological age (BA-CA); E, mean esti-
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differences in final height between sexes are contradictory 
(7). Some studies reported decreased pubertal growth in 
boys (2, 30), potentially because CAH in boys was diag-
nosed at a later age than in girls before neonatal screening 
became standard of care (4, 30-32).
We saw a trend that final height estimation decreased 
with the severity of the genetic mutation in CYP21A2, 
which correlates well with 21-hydroxylase enzyme ac-
tivity, but results were not statistically significant due to 
low sample size.
Final height estimations were better with low 17-OHP 
in adrenarche, and with high androstenedione levels in pu-
berty. While the first finding informs about good metabolic 
control, the latter correlates with gonadal activation of sex 
hormone production stimulating growth.
Bone age is usually used as a clinical marker for meta-
bolic control in CAH, with accelerated bone age indicating 
glucocorticoid undertreatment (1). To achieve adequate 
final height in growing CAH patients with advanced bone 
age, international guidelines recommend increasing gluco-
corticoid dosage or considering height-promoting ther-
apies, such as growth hormone treatment or aromatase 
inhibitors for CAH patients with a height of <−2.25 SDS 
(33). However, our CAH patients with and without signifi-
cant bone age advancement, and thus differing final height 
prediction during adrenarche, had similar final height out-
comes, when reassessed during puberty or reaching final 
height. This finding was unexpected, and we still search for 
an explanation. Looking at the old literature from Tanner 
et al, a similar growth pattern has been described for early 
and late bloomers, in whom bone age differed during pu-
berty and hinted a higher final height outcome for late 
bloomers, but actual final height was same in both (26, 
34). For our CAH patients, final height predictions using 
Table 2. Auxological data of patients
All patients Boys Girls
 N = 41  N = 15  N = 26  
n Mean SD n Mean SD n Mean SD P valuec
Final height, cm    7 176.4 7.1 20 160.1 4.8 0.001
Final height SDS 27 -0.4 0.8 7 -0.2 1.0 20 -0.5 0.7 0.267
 Accelerating patients 11 -0.4 0.7 3 0.0 1.0 8 -0.6 0.6 0.414
 Nonaccelerating patients 16 -0.3 0.9 4 -0.1 1.1 12 -0.4 0.8 0.626
Parental target height, cm    15 179.2 4.2 26 163.7 4.5 0.001
Parental target height SDS 41 0.2 0.6 15 0.4 0.6 26 0.1 0.7 0.194
Corrected final height SDSa 27 -0.6 1.0 7 -0.2 1.2 20 -0.8 0.9 0.184
Mean height SDSb
 Before adrenarche 41 -0.7 1.0 15 -0.2 0.9 26 -0.9 1.0 0.110
 Adrenarche 41 0.1 1.1 15 0.7 0.9 26 -0.2 1.0 0.004
 Puberty 36 0.0 1.0 11 0.5 0.9 25 -0.3 0.9 0.031
Growth from G2/B2 to final height (cm) 27 20.7 6.4 7 22.5 8.3 20 20.1 5.8 0.543
Mean growth velocity SDSb
 Before adrenarche 41 0.6 1.2 15 1.2 1.0 26 0.3 1.0 0.006
 Adrenarche 41 0.5 0.7 15 0.6 0.8 26 0.4 0.7 0.427
 Puberty 36 0.2 0.7 11 0.3 0.7 25 0.2 0.7 0.693
Bone age − chronological ageb
 Before adrenarche 41 -0.5 0.7 15 -0.3 0.6 26 -0.6 0.7 0.256
 Adrenarche 41 0.1 1.4 15 0.3 1.4 26 -0.1 1.4 0.417
 Puberty 36 0.3 1.1 11 0.4 1.0 25 0.3 1.1 0.878
Mean estimated final height SDS according to Bayley and Pinneaub
 Before adrenarche 41 -0.3 0.9 15 -0.1 0.9 26 -0.4 0.8 0.48
 Adrenarche 40 -0.3 1.2 15 0.3 1.0 25 -0.7 1.1 0.011
 Puberty 35 -0.4 1.1 11 0.3 1.1 24 -0.7 0.9 0.021
Mean estimated final height SDS according to Bonfig and Schwarzb
 Adrenarche 37 -1.3 1.1 15 0.3 1.0 22 -2.3 1.0 0.001
 Puberty 34 -0.8 1.2 11 0.3 1.1 23 -1.3 1.0 0.007
Table presents number (n), mean, and SD of auxological data of all patients combined, and divided for boys and girls.
aFinal height SDS − target height SDS.
bMean calculated for each period per individual patient.
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Figure 3. Growth data of CAH children showing accelerating or nonaccelerating bone age. Shown are dichotomized growth data of accelerating and 
nonaccelerating CAH children, and of all patients combined, depicted as line graphs and divided into 3 age groups: before adrenarche, adrenarche, 
and puberty. From top left to bottom right, parameters depicted are A, individual bone age − chronological age (BA-CA) of accelerating individuals 
(black) vs nonaccelerating (light gray) over time; B, mean BA-CA; C, individual height of accelerating individuals (black) vs nonaccelerating (light 
gray) over time; D, mean height SDS; E, mean growth velocity SDS; F, mean BMI SDS; G, mean estimated height SDS according to Bayley and 
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the Bayley-Pinneau method (24) were most accurate to real 
final height, while the Bonfig and Schwarz method (25) 
underestimated final height at both time points adrenarche 
and puberty. Thus, bone age and height predictions should 
be treated with caution, and additional diagnostic, such 
as biochemical parameters, might help to monitor meta-
bolic control in CAH children. Our data indicate that bone 
age alone should not be used during adrenarche as clinical 
marker for metabolic control in CAH treatment.
Adrenal androgens are produced in the zona reticularis 
(zR) of the adult adrenal cortex after adrenarche. The fetal 
adrenal involutes in the first weeks after birth and gives 
rise to an adult adrenal cortex, which consists initially 
only of the mineralocorticoid producing zona glomerulosa 
and glucocorticoid producing zona fasciculata (35-37). 
The zR forms continuously during infancy and becomes 
functionally active with adrenarche after the age of 6 to 
9 years (38). Androgen precursors dehydroepiandrosterone 
(DHEA) and its sulfate ester (DHEAS), androstenedione, 
and 11-hydroxy-androstenedione are then produced in the 
zR and released into circulation and the intermediate me-
tabolism where they may be converted to active 11-oxygen-
ated androgens, such as 11-keto-testosterone (39). So far, 
adrenarche has been defined by serum DHEAS ≥ 1 µmol/L 
biochemically (14), and by first appearance of pubic and 
axillary hair and adult-type body odor clinically (14, 
40). However, clinical signs (pubarche) and biochemical 
markers (DHEAS) of adrenarche can be dissociated, as 
shown in girls with Turner syndrome (41), or misleading, 
as shown in CAH (42). Several studies have shown that 
pubarche appears earlier in CAH children than in healthy 
controls (28, 43, 44). Other studies have found low serum 
DHEAS levels in well-controlled children with classic CAH 
when compared to healthy controls regardless of their age 
(42, 45, 46). Therefore, authors concluded that it is diffi-
cult to define adrenarche in patients with CAH using the 
current clinical or biochemical definition, and that CAH 
patients might not have an adrenarche at all (42, 45, 47). 
Defining adrenarche biochemically was impossible in our 
patients because they had low DHEA/S (androgen) levels 
throughout childhood and adolescence, in line with other 
studies (42, 44, 47, 48). Glucocorticoid therapy of CAH 
suppresses adrenal androgens, influencing the physiological 
timing of pubic hair appearance (pubarche). Therefore, we 
defined the time period of adrenarche as between age of 
6 years to the onset of puberty.
Figure 4. Coefficient plots showing factors associated with height outcome in CAH. This figure shows linear mixed effects models to identify factors 
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Strength and Limitations
A limitation we share with most other studies on growth in 
CAH patients is the retrospective design. This may explain 
the observed difference in sex ratio from the expected 1:1 
sex ratio in CAH. Boys with CAH may be more likely than 
girls to drop out of follow-up care; thus, the participating 
clinics may have missed a few during patient identification. 
In Switzerland, children with CAH see their treating pedi-
atric endocrinologist in at least 6-monthly intervals. This 
may have led to underestimation of the age at puberty. 
We therefore used a defined age range from 6 to 9 years 
to determine bone age progression during adrenarche to 
exclude pubertal growth spurt. The relatively low sample 
size led to wide confidence intervals for subgroups of CAH 
patients. Thus, we may have missed detecting differences 
in height outcomes between patients with accelerating and 
nonaccelerating bone age, or differences between genetic 
subgroups on estimated final height. But the slightly smaller 
adult height in our CAH children compared with their peers 
has no clinical significance. Studies with a larger number of 
patients are important to confirm our findings and may be 
feasible through collaborative efforts using an international 
registry such as the I-CAH (https://home.i-cah.org/). Only 
two-thirds of our CAH patients had reached final height 
during the time of the study. In a follow-up study, when 
all patients have achieved final height, we will be able to 
draw more robust conclusions whether, and to which ex-
tent, bone age progression influences final height.
We used 2 established methods to describe estimated 
final height in CAH. Bayley and Pinneau developed a 
method to predict final height from bone age progression 
in healthy children (24). To avoid overestimation of final 
height in CAH children, we calculated all final height pro-
jections using the Bayley and Pinneau method assuming 
that bone age was adequate for chronological age. We 
also used the method by Bonfig and Schwarz, which they 
adapted specifically for children with classic CAH (25). In 
our setting, predictions using average values of Bayley and 
Pinneau were closer to final height than when using Bonfig 
and Schwarz predictions.
Conclusion
CAH patients under recommended near-physiologic gluco-
corticoid treatment achieve a final height that is close to 
normal. Although a growth acceleration and bone age 
progression can be observed in almost 50% of children 
during the years of adrenarche, this does not result in a 
more compromised (predicted) final height compared with 
CAH children who do not have bone age progression 
during adrenarche. Thus, bone age may not be the best 
marker of metabolic control in CAH patients during the 
period of adrenarche, and additional growth-promoting 
treatments in otherwise well-controlled CAH patients seem 
unnecessary.
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